Codiak’s exosomes could offer new tack to STING agonism

Exosome company Codiak BioSciences Inc. (Cambridge, Mass.) on Tuesday provided a first glimpse of preclinical data for its exoSTING program, with a therapy that is among the next generation of STING agonists that go beyond intratumoral dosing of free compounds.

Data were presented in an abstract released ahead of the Society for Immunotherapy in Cancer meeting, which runs Nov. 7-11 in Washington. Aduro Biotech Inc. (NASDAQ:ADRO) will also present Phase I data at the meeting for its STING agonist, ADU-S100 (MIW815)...